Kymera Investor Day Presentation Deck

Sanofi - Rich Immunology portfolio extending to other TAs Dermatology DupixentⓇ Amlitelimab(2) Rilzabrutinib SAR444727 topical BTKi SAR444656(1) IRAK4 degrader SAR443726 Anti IL13/OX40L nanob. SAR443122(3) RIPK1i *THOR809 SANOFI Respiratory DupixentⓇ Itepekimab Rilzabrutinib *anti-IL-13-TSLP NANOBODYⓇ GI DupixentⓇ *Bispecific NANOBODYⓇ Type 2 Type 2+ mixed Gl: gastrointestinal; TCE: T cell engager; NKCE: NK cell engager Rheumatology *= preclinical All assets except for Dupixent®, Libtayo®, Sarclisa®, AubagioⓇ (3) and LemtradaⓇ are under investigation and are not approved by (4) Rilzabrutinib Anti-CD40L mAb(4) Autoantibody KevzaraⓇ *Bispecific NANOBODYⓇ any regulators (1) (2) Hematology Neurology Sutimlimab Rilzabrutinib Isatuximab SAR445088 Complement C1s inh Immunoregulatory (5) Developed in collaboration with Kymera (KT474) (6) Anti-OX40L mAb, formerly known as KY1005/SAR445229 (7) In collaboration with Denali (8) In collaboration with Immunext AubagioⓇ Tolebrutinib Anti-CD40L mAb(4) SAR445088 Complement C1s inh. LemtradaⓇ SAR443820(3) RIPK1i Th1/Th17 Oncology LibtayoⓇ SarclisaⓇ SAR442257 CD38xCD28xCD3 SAR444245(6) Non-alpha IL-2 SAR445419(7) K-NK. SAR439459 Anti-TGFb mAB *NKCE(8) Immunostimulatory Pending closure of Kiadis acquisition Formerly known as THOR707 Formerly known KDS1001 (Kiadis) In collaboration with Innate Pharma 46

View entire presentation